natgillin/translations-raw huggingface dataset:
• pain due to diabetic peripheral neuropathy (damage to the nerves in the feet, legs, hands and arms that can occur in patients with diabetes);
• valu, mida põhjustab diabeetiline perifeerne neuropaatia (jalgade ja käte närvikahjustus, mida võib esineda diabeediga patsientidel);
A risk management plan has been developed to ensure that Duloxetine Zentiva is used as safely as possible.
Töötati välja riskijuhtimiskava, et tagada Duloxetine Zentiva võimalikult ohutu kasutamine.
Since these neurotransmitters are involved in maintaining mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.
Et kõnealused neurotransmitterid osalevad hea meeleolu säilitamises ja valutunde vähendamises, võib nende närvirakkudesse tagasihaarde pärssimine leevendada depressiooni, ärevuse ja neuropaatilise valu sümptomeid.
The Committee recommended that Duloxetine Zentiva be approved for use in the EU.
Komitee soovitas Duloxetine Zentiva kasutamise Euroopa Liidus heaks kiita.
Duloxetine Zentiva is available as gastroresistant capsules (30 and 60 mg).
Duloxetine Zentivat turustatakse gastroresistentsete kapslitena (30 ja 60 mg).
What measures are being taken to ensure the safe and effective use of Duloxetine Zentiva?
Mis meetmed võetakse, et tagada Duloxetine Zentiva ohutu ja efektiivne kasutamine?
Duloxetine Zentiva is used to treat adults with the following diseases:
Duloxetine Zentivat kasutatakse järgmiste haiguste raviks täiskasvanutel:
In patients who respond to Duloxetine Zentiva, treatment should continue for several months, to prevent the disorder coming back.
Patsiendid, kellel tekib Duloxetine Zentivale ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist.
For major depression, the recommended dose of Duloxetine Zentiva is 60 mg once a day.
Raske depressiooni raviks on Duloxetine Zentiva soovitatav annus 60 mg üks kord ööpäevas.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Duloxetine Zentiva has been shown to have comparable quality to Cymbalta and to be bioequivalent to Cymbalta.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Duloxetine Zentiva võrreldav kvaliteet ja bioekvivalentsus ravimiga Cymbalta.
For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of up to 120 mg per day.
Diabeetilise neuropaatilise valu raviks on soovitatav annus 60 mg üks kord ööpäevas, kuid mõnel patsiendil võib olla vaja suuremat annust kuni 120 mg ööpäevas.
In patients who respond to Duloxetine Zentiva, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.
Zentivale ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist; samuti peavad ravimi võtmist jätkama patsiendid, kellel on varem olnud korduvaid depressiooniepisoode.
Other information about Duloxetine Zentiva
Muu teave Duloxetine Zentiva kohta
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duloxetine Zentiva, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Duloxetine Zentiva omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
This is a summary of the European public assessment report (EPAR) for Duloxetine Zentiva.
See on ravimi Duloxetine Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between nerve cells, increasing the level of communication between the cells.
Neurotransmitterite tagasihaarde pärssimise kaudu suurendab duloksetiin nende arvu närvirakkude vahel, suurendades rakkudevahelist signaalivahetust.
What is Duloxetine Zentiva and what is it used for?
Mis on Duloxetine Zentiva ja milleks seda kasutatakse?
The active substance in this medicine, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Duloxetine Zentiva toimeaine duloksetiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor.
For practical information about using Duloxetine Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate Duloxetine Zentiva kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
This means that Duloxetine Zentiva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Cymbalta.
See tähendab, et Duloxetine Zentiva on sarnane võrdlusravimiga Cymbalta, millel juba on Euroopa Liidus müügiluba.
Duloxetine Zentiva contains the active substance duloxetine and is is a ‘generic medicine'.
Duloxetine Zentiva sisaldab toimeainena duloksetiini ja on geneeriline ravim.
For more information about treatment with Duloxetine Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Duloxetine Zentivaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Because Duloxetine Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Et Duloxetine Zentiva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
The dose of Duloxetine Zentiva should be reduced gradually when stopping treatment.
Ravi katkestamisel tuleb Duloxetine Zentiva annust vähendada järk-järgult.
Because Duloxetine Zentiva is a generic medicine of Cymbalta, its benefits and risks are taken as being the same as the reference medicine's.
Et Duloxetine Zentiva on Cymbalta geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
It is not intended to provide practical advice on how to use Duloxetine Zentiva.
Hindamisaruandes ei anta Duloxetine Zentiva kasutamise praktilisi nõuandeid.
Therefore, the CHMP's view was that, as for Cymbalta, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Cymbalta korral, ületab ravimi Duloxetine Zentiva kasulikkus sellega kaasnevad riskid.
Why is Duloxetine Zentiva approved?
Miks Duloxetine Zentiva heaks kiideti?
Duloxetine Zentiva duloxetine
Duloxetine Zentiva duloksetiin
How has Duloxetine Zentiva been studied?
Kuidas Duloxetine Zentivat uuriti?
How is Duloxetine Zentiva used?
Kuidas Duloxetine Zentivat kasutatakse?
How does Duloxetine Zentiva work?
Kuidas Duloxetine Zentiva toimib?
What are the benefits and risks of Duloxetine Zentiva?
Milles seisneb Duloxetine Zentiva kasulikkus ja mis riskid ravimiga kaasnevad?
Oncaspar received a marketing authorisation valid throughout the EU on 14 January 2016.
Oncaspar on saanud müügiloa, mis kehtib kogu Euroopa Liidus, 14. jaanuaril 2016.
Further information on Oncaspar can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR Oncaspar.
Lisateave Oncaspari kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR Oncaspar.
Oncaspar (pegaspargase)
Oncaspar (pegaspargaas)
The healthcare professional should give the medicine in a hospital where resuscitation equipment is available.
Meditsiinitöötaja peab ravimit manustama haiglas, kus on olemas elustamisvahendid.
What measures are being taken to ensure the safe and effective use of Oncaspar?
Mis meetmeid võetakse, et tagada Oncaspari ohutu ja efektiivne kasutamine?
However, the data in adult patients were limited and the company that markets the medicine is to provide further data of its benefit in this group of patients.
Täiskasvanud patsientide andmed olid siiski piiratud ja ravimit turustaja esitab täiendavad andmed ravimi kasulikkuse kohta selles patsiendirühmas.
Other information about Oncaspar
Muu teave Oncaspari kohta
The European Medicines Agency therefore decided that Oncaspar's benefits are greater than its risks and it can be authorised for use in the EU.
Euroopa Ravimiamet otsustas, et Oncaspari kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
Oncaspar is used in combination with other cancer medicines.
Oncaspari kasutatakse koos teiste vähiravimitega.
As for all medicines, data on the use of Oncaspar are continuously monitored.
Nagu kõigi ravimite puhul, teostatakse Oncaspari kasutamise kohta pidevat järelevalvet.
As for its risks, the side effects of Oncaspar are similar to those of other asparaginase medicines and are considered manageable
Riskide osas sarnanevad Oncaspari kõrvalnähud muude asparaginaasi sisaldavate ravimite kõrvalnähtudega ja neid peetakse hallatavateks.
What is Oncaspar and what is it used for?
Mis on Oncaspar ja milleks seda kasutatakse?
The company that markets Oncaspar will complete two more studies on the safety and effectiveness of Oncaspar, which will help further clarify the benefits and risks of this medicine in adults and in newly diagnosed patients.
Oncasparit turustaja lõpetab kaks täiendavat uuringut Oncaspari ohutuse ja efektiivsuse kohta, mis aitavad täiendavalt selgitada ravimi kasulikkust ja riske täiskasvanutel ning esmadiagnoosiga patsientidel.
For more information about using Oncaspar, see the package leaflet or contact your doctor or pharmacist.
Lisateavet Oncaspari kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
Side effects reported with Oncaspar are carefully evaluated and any necessary action taken to protect patients.
Oncaspari kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
The most common side effects with Oncaspar (which may affect more than 1 in 10 people) include signs of liver problems (raised levels of liver enzymes and bilirubin in the blood), reduced blood clotting, high levels of fats in the blood, high levels of blood glucose and low levels of white blood cells accompanied by fever.
Oncaspari kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on maksaprobleemide nähud (maksaensüümide suurenenud sisaldus veres), vere vähenenud hüübimine, vere suur rasvasisaldus, vere suur glükoosisisaldus ja leukotsüütide (vere valgeliblede) vähesus koos palavikuga.
Oncaspar also comes with the advantage of requiring fewer injections as the medicine stays longer in the body than some other asparaginases.
Oncaspari eelis on väiksem arv süste, sest ravim püsib organismis kauem kui mõni muu asparaginaasravim.
What are the risks associated with Oncaspar?
Mis riskid Oncaspariga kaasnevad?
The cancer cells need this amino acid to grow and multiply, and so its reduction in the blood causes the cells to die.
Vähirakud vajavad seda aminohapet kasvamiseks ja paljunemiseks, seega põhjustab selle väiksem sisaldus veres nende rakkude hävimise.
The asparaginase enzyme in this medicine is linked to a chemical which slows down its removal from the body and can reduce the risk of allergic reactions.
Ravimis sisalduv ensüüm asparaginaas on seotud keemilise ainega, mis pikendab selle püsimist organismis ja vähendab allergiareaktsioonide riski.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oncaspar have been included in the summary of product characteristics and the package leaflet.
Oncaspari ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Studies showed Oncaspar to be effective in patients with ALL, including patients who were allergic to asparaginase.
Uuringud tõendasid, et Oncaspar on efektiivne ägeda lümfoblastleukeemiaga patsientidel, sealhulgas nendel, kes on allergilised asparaginaasi suhtes.
In another study of 76 children whose cancer returned after earlier treatment, around 40% of Oncaspar-treated patients (some of whom were allergic to other asparaginase treatments) were cleared of the cancer, compared with 47% of patients treated with an asparaginase comparator.
Teises uuringus, milles osales 76 pärast varasemat ravi taastekkinud vähiga last, oli ravi järel ilma vähita patsiente Oncaspari uuringurühmas ligikaudu 40% (kellest osa oli allergiline muude asparaginaasravimite suhtes) ja asparaginaasi sisaldava võrdlusravimi rühmas 47%.
The active substance (pegaspargase) contains the enzyme asparaginase which works by breaking up and reducing the blood levels of the amino acid asparagine.
Toimeaine (pegaspargaas) sisaldab ensüümi asparaginaasi, mis lõhustab aminohapet asparagiini ja vähendab selle sisaldust veres.
How does Oncaspar work?
Kuidas Oncaspar toimib?
In a study in 118 children newly diagnosed with ALL, 75% of those treated with Oncaspar (in combination with other medicines) were free of the cancer after 7 years, without having relapse or a new cancer during that period.
Uuringus, milles osales 118 ägeda lümfoblastleukeemia esmadiagnoosiga last, oli patsiente, kellel ei esinenud vähki 7 aastat pärast ravi ega tekkinud relapsi või uut vähki, Oncaspariga (kombinatsioonis teiste ravimitega) ravitutest 75% ja muu asparaginaasiga ravitutest 66%.
For the full list of side effects of Oncaspar, see the package leaflet.
Oncaspari kõrvalnähtude täielik loetelu on pakendi infolehel.
How is Oncaspar used?
Kuidas Oncasparit kasutatakse?
Oncaspar must not be used in patients with severe liver disease, patients who have ever had pancreatitis (including pancreatitis caused by previous asparaginase treatments) or patients who have had severe bleeding or serious blood clots following asparaginase treatment.
Oncasparit ei tohi kasutada raske maksahaigusega patsiendid ega patsiendid, kellel on esinenud pankreatiit või kellel on pärast asparaginaasravi tekkinud raske verejooks või raske tromboos.
Oncaspar can only be obtained with a prescription and only healthcare professionals with experience of cancer treatments should prescribe and give the medicine.
Oncaspar on retseptiravim, mida tohivad määrata ja manustada üksnes vähiravis kogenud tervishoiutöötajad.
What benefits of Oncaspar have been shown in studies?
Milles seisneb uuringute põhjal Oncaspari kasulikkus?
It contains the active substance pegaspargase.
Oncaspar sisaldab toimeainena pegaspargaasi.
Oncaspar is normally given every 14 days by injection into a muscle or by infusion (drip) into a vein, with the dose depending on age and body surface area.
Oncasparit manustatakse tavaliselt iga 14 päeva järel intramuskulaarse süstena või veeniinfusioonina.
An overview of Oncaspar and why it is authorised in the EU
Ülevaade ravimist Oncaspar ja ELis müügiloa väljastamise põhjendus
Oncaspar is a cancer medicine used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts.
Oncaspar on vähiravim, mis on näidustatud ägeda lümfoblastleukeemia (ALL) raviks täiskasvanutel ja lastel.
Orfadin nitisinone
Orfadin nitisinoon
What measures are being taken to ensure the safe and effective use of Orfadin?
Mis meetmed võetakse, et tagada Orfadini ohutu ja efektiivne kasutamine?
Orfadin is intended for long-term use.
Orfadin on ette nähtud pikaajaliseks kasutamiseks.
The European Commission granted a marketing authorisation valid throughout the European Union for Orfadin on 21 February 2005.
Euroopa Komisjon andis Orfadini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. veebruaril 2005.
A risk management plan has been developed to ensure that Orfadin is used as safely as possible.
Töötati välja riskijuhtimiskava, et tagada Orfadini võimalikult ohutu kasutamine.
It is available as capsules (2 mg, 5 mg, 10 mg and 20 mg) and as a suspension (4 mg/ml) to be taken by mouth.
Seda turustatakse kapslitena (2 mg, 5 mg, 10 mg ja 20 mg) ja suukaudse suspensioonina (4 mg/ml).
The largest study of Orfadin was carried out in 257 patients in 87 different hospitals in 25 countries, as part of a ‘compassionate-use' programme.
Orfadini suurim uuring, milles osales 25 riigi 87 haigla 257 patsienti, toimus eriloaga kasutamise programmi alusel.
This is a programme through which doctors can request a medicine for one of their patients before the medicine is fully authorised.
See on programm, mille kaudu arstid võivad taotleda ravimi kasutamist mõnel patsiendil teatud haiguse ravimiseks enne ravimi täieliku müügiloa andmist.
Thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), granulocytopenia (low levels of granulocytes, a type of white blood cell), conjunctivitis (inflammation of the membrane that lines the eyelid), corneal opacity (clouding of the cornea, the transparent layer in front of the pupil), keratitis (inflammation of the cornea), photophobia (increased sensitivity of the eyes to light) and eye pain are also common (seen in between 1 and 10 patients in 100).
Trombotsütopeenia (vereliistakute vähesus), leukopeenia (vere valgeliblede vähesus), granulotsütopeenia (vere teatud valgeliblede granulotsüütide vähesus), konjunktiviit (silma sidekesta põletik), silma sarvkesta hägusus, keratiit (sarvkestapõletik), fotofoobia (valguskartus) ja silmavalu on samuti sagedad (esinenud 1-10 patsiendil 100st).
This is a summary of the European public assessment report (EPAR) for Orfadin.
See on ravimi Orfadin Euroopa avaliku hindamisaruande kokkuvõte.
The summary of the opinion of the Committee for Orphan Medicinal Products for Orfadin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Orfadini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
This is a rare disease in which the body is unable to completely break down the amino acid tyrosine, and harmful substances are formed, causing serious liver problems and liver cancer.
See on haruldane haigus, mille korral organism ei suuda täielikult lagundada aminohapet türosiini, mille tulemusena tekivad kahjulikud ained, mis põhjustavad raskeid maksaprobleeme ja maksavähki.
Therefore, the CHMP decided that Orfadin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas inimravimite komitee, et Orfadini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP noted that Orfadin seems to be an effective treatment for HT-1, particularly if it is started early, before the patient's liver is too damaged.
Inimravimite komitee märkis, et Orfadin näib olevat HT-1 ravis efektiivne, eelkõige kui selle kasutamist alustatakse vara, enne patsiendi maksa liigset kahjustumist.
As the company had submitted the additional information requested, the ‘exceptional circumstances' ended on 21 September 2009.
Et ettevõte esitas soovitud lisateabe, tühistati 21. septembril 2009 müügiloa erandkorras väljastatus.
Treatment should be started as early as possible and the dose of Orfadin adjusted according to the patient's response and body weight.
Ravi tuleb alustada nii vara kui võimalik ning Orfadini annus tuleb kohandada patsiendi ravivastuse ja kehakaalu järgi.
Treatment with Orfadin leads to high levels of tyrosine in the blood (due to the medicine's mode of action); this side effect is seen in more than 1 patient in 10.
Orfadiniga toimuva ravi tagajärjel suureneb türosiinisisaldus veres (ravimi toimemehhanismi tõttu); see kõrvalnäht esineb enam kui 1 patsiendil 10st.
Orfadin was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of the approval.
Esialgu kiideti Orfadin heaks erandkorras, sest haigus esineb harva ja ravimi heakskiitmise ajal ei olnud piisavalt teavet.
The recommended starting dose is 1 mg per kilogram body weight per day, divided into two doses.
Soovitatav lähteannus on 1 mg kehakaalu kg kohta ööpäevas, jagatuna kaheks annuseks.
Orfadin is used to treat hereditary tyrosinaemia type 1 (HT-1).
Orfadini kasutatakse päriliku I tüüpi türosineemia (HT-1) raviks.
Why has Orfadin been approved?
Miks Orfadin heaks kiideti?
Because the number of patients with HT-1 is low, the disease is considered ‘rare', and Orfadin was designated an ‘orphan medicine' (a medicine used in rare diseases) on 29 December 2000.
Et HT-1-ga patsientide arv on väike ja see haigus esineb harva, nimetati Orfadin 29. detsembril 2000 harvikravimiks.
What is Orfadin?
Mis on Orfadin?
The main benefit of Orfadin is to greatly extend life expectancy.
Orfadini peamine kasulikkus on oluliselt suurenenud elulemus.
Other information about Orfadin
Muu teave Orfadini kohta
For the full list of all side effects and restrictions with Orfadin, see the package leaflet.
Orfadini kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
These amino acids are normally found in proteins in foods and drinks.
Need aminohapped on tavalistes toiduvalkudes.
Orfadin is a medicine that contains the active substance nitisinone.
Orfadin on ravim, mis sisaldab toimeainena nitisinooni.
For example, a baby less than two months old with HT-1 would normally have only a 28% chance of surviving for five years using a modified diet alone.
Näiteks üksnes eridieeti kasutades on HT-1-ga alla 2-kuusel imikul tõenäosus elada 5-aastaseks ainult 28%.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Orfadin, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati Orfadini omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
What is the risk associated with Orfadin?
Mis riskid Orfadiniga kaasnevad?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Orfadin.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
Patients with HT-1 lack one of these enzymes, so tyrosine is not properly eliminated but is transformed into harmful substances.
HT-1-ga patsientidel puudub neist üks ensüüm, mille tõttu jääb türosiin organismi ja see muutub kahjulikeks aineteks.
Many of these side effects can be the result of high tyrosine levels caused by patients not eating the right foods.
Neist kõrvalnähtudest mitut põhjustab suur türosiinisisaldus, mis tuleneb valest toitumisest.
However, as tyrosine remains in the body during Orfadin treatment, patients need to eat a special diet low in tyrosine.
Et türosiin püsib Orfadini-ravi ajal organismis, vajavad patsiendid siiski eridieeti, mis sisaldab türosiini vähe.
How does Orfadin work?
Kuidas Orfadin toimib?
The active substance in Orfadin, nitisinone, blocks an enzyme that converts tyrosine into harmful substances.
Orfadini toimeaine nitisinoon blokeerib türosiini kahjulikeks aineteks muutva ensüümi.
The oral suspension is for children who have difficulty swallowing capsules.
Suukaudne lahus on ette nähtud lastele, kes ei suuda neelata kapsleid.
The study looked at the effect of Orfadin on survival, and compared this with reports published in medical journals describing survival in patients with HT-1 who were only receiving a modified diet.
Uuringu tulemusi võrreldi meditsiini teadusajakirjades avaldatud andmetega nende HT-1-ga patsientide kohta, kes kasutasid ainult eridieeti.
What benefit has Orfadin shown during the studies?
Milles seisneb uuringute põhjal Orfadini kasulikkus?
Orfadin also provides a better outcome for patients than that reported in the literature in patients eating a modified diet alone.
Orfadin mõjub patsiendile ka paremini kui üksnes eridieet, mille kohta on andmed teaduskirjandusest.
Treatment with Orfadin should be started and monitored by doctors who have experience in the treatment of patients with HT-1.
Ravi Orfadiniga tohib alustada üksnes HT-1-ga patsientide ravis kogenud arst ning ravi peab toimuma tema järelevalve all.